Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05593770
Other study ID # ACTIV-4
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date October 27, 2022
Est. completion date February 1, 2024

Study information

Verified date March 2024
Source NEAT ID Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.


Description:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. The clinical spectrum of COVID-19 infection is broad, encompassing asymptomatic infection, mild upper respiratory tract illness, and severe viral pneumonia with respiratory failure and death. Between 13 and 40% of patients become hospitalized, up to 30% of those hospitalized require admission for intensive care, and there is a 13% inpatient mortality rate. The reasons for hospitalization include respiratory support, as well as support for failure of other organs, including the heart and kidneys. The risk of thrombotic complications is increased, even when compared to other viral respiratory illnesses, such as influenza. While 82% of hospitalized patients with COVID-19 are ultimately discharged alive, median length of stay is 10-13 days. Early work in treating COVID-19 has focused on preventing worsening of the initial clinical presentation to prevent hospitalization and disease progression to organ failure and death. Studies conducted under this Master Host Tissue Protocol are expected to extend our knowledge of how to manage patients who are hospitalized for COVID-19 illness. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19. This Master Protocol is a randomized, placebo-controlled trial of agents targeting the host response in COVID-19 in hospitalized patients with hypoxemia. The Master Host Tissue Protocol is designed to be flexible in the number of study arms, the use of a single placebo group, and the stopping and adding of new therapies. Our primary outcome is oxygen free days through day 28. This is defined as days alive and without supplemental oxygen use during the first 28 days following randomization. Patients who die on or before day 28 are assigned -1 oxygen free days.


Recruitment information / eligibility

Status Terminated
Enrollment 28
Est. completion date February 1, 2024
Est. primary completion date December 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Hospitalized for COVID-19 2. =18 years of age 3. SARS-CoV-2 infection, documented by: 1. nucleic acid test (NAT) or equivalent testing within 3 days prior to randomization OR 2. documented by NAT or equivalent testing more than 3 days prior to randomization AND progressive disease suggestive of ongoing SARS-CoV-2 infection per the responsible investigator (For non-NAT tests, only those deemed with equivalent specificity to NAT by the protocol team will be allowed. A central list of allowed non- NAT tests is maintained in Appendix E. Appendix E. Non-NAT Tests Deemed with Equivalent Specificity to NAT by the Protocol Team). 4. Hypoxemia, defined as SpO2 <92% on room air, new receipt of supplemental oxygen to maintain SpO2 =92%, or increased supplemental oxygen to maintain SpO2 =92% for a patient on chronic oxygen therapy 5. Symptoms or signs of acute COVID-19, defined as one or more of the following: 1. cough 2. reported or documented body temperature of 100.4 degrees Fahrenheit or greater 3. shortness of breath 4. chest pain 5. infiltrates on chest imaging (x-ray, CT scan, lung ultrasound) Exclusion Criteria: 1. Onset of COVID-19 symptom fulfilling inclusion criterion #5 >14 days prior to randomization 2. Hospitalized with hypoxemia (as defined in inclusion #4) for >72 hours prior to randomization (the 72-hour window for randomization begins when the patient first meets the hypoxemia inclusion criteria after hospital admission) 3. Pregnancy 4. Breastfeeding 5. Prisoners 6. End-stage renal disease (ESRD) on dialysis 7. Patient undergoing comfort care measures only such that treatment focuses on end-of- life symptom management over prolongation of life. 8. The treating clinician expects inability to participate in study procedures or participation would not be in the best interests of the patient 9. Known allergy/hypersensitivity to IMP or its excipients Fostamatinib Arm-Specific Exclusion Criteria: The following exclusion criteria differ from the master protocol criteria: 1. Randomized in another trial evaluating fostamatinib in the prior 30 days Study arm exclusion criteria measured within 24 hours prior to randomization: 1. AST or ALT = 5 × upper limit of normal (ULN) or ALT or AST = 3 × ULN and total bilirubin = 2 × ULN 2. SBP > 160 mmHg or DBP > 100 mmHg at the time of screening and randomization 3. ANC < 1000/mL 4. Patient is anticipated to require a strong CYP3A inhibitor (Atazanavir, Certinib, Clarithromycin, Cobicistat and cobicistat-containing coformulations, Idelalisib,Indinavir, Itraconazole, Ketoconazole, Levoketoconazole, Lonafarnib, Lopinavir, Mifeprostone, Mibefradil, Nefazodone, Nelfinavir, Ombitasvir-paritaprevir-ritonavir plus dasabuvir, Posaconazole, Ribociclib Ritonavir, Saquinavir, Telithromycin, Troleandomycin, Tucatinib, Voriconazole) from randomization to 21 days post-randomization. For a full list of CYP3A4 substrates, please reference this regularly updated list: https://drug-interactions.medicine.iu.edu/MainTable.aspx. 5. Patient unable to participate or declines participation in the fostamatinib arm.

Study Design


Intervention

Drug:
Fostamatinib
Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Placebo
Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.

Locations

Country Name City State
Brazil Hospital de Clínicas de Porto Alegre Porto Alegre
Brazil Hospital Federal dos Servidores do Estado Rio De Janeiro
Brazil Instituto Nacional de Infectologia Evandro Chagas Rio De Janeiro
Germany University Hospital Bonn Bonn
Germany University of Frankfurt Frankfurt
Italy Ente Ospedaliero Ospedali Galliera Genova
Italy San Paolo Hospital - ASST Santi Paolo e Carlo Milan
Italy San Raffaele Turro Hospital Milan
Italy University of Milan Milan
South Africa Worthwhile Clinical Trials (WWCT Lakeview Hospital) Benoni
South Africa Clinical HIV Research Unit - Helen Joseph Hospital (WITS CHRU) Johannesburg
South Africa Global Clinical Trials (Pty) Ltd Pretoria
Spain Hospital General Universitario de Elche Alicante
Spain Hospital Clinic Barcelona Barcelona Villarroel
Spain Hospital del Mar Barcelona
Spain Hospital Universitario Vall d'Hebron Barcelona
Spain Hospital Clinico San Carlos Madrid
Spain Hospital Universitario Fundacion Alcorcon Madrid
Spain Hospital Universitario Ramón y Cajal Madrid
Spain Universidad de Valladolid - Hospital Universitario Río Hortega Valladolid
Spain Hospital Clinico Universitario Lozano Blesa Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
NEAT ID Foundation

Countries where clinical trial is conducted

Brazil,  Germany,  Italy,  South Africa,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Oxygen free days through day 28 This is defined as days alive and without supplemental oxygen use during the first 28 days following randomization. Patients who die on or before day 28 are assigned -1 oxygen free days. Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO). Day 1 to Day 28
Secondary In-hospital mortality Proportion of patients who die during hospitalization Day 1 to hospital discharge or Day 90 whichever comes first
Secondary Alive and oxygen free at Day 14 Proportion of patients oxygen free at day 14. Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO). Day 1 to Day 14
Secondary Alive and oxygen free at Day 28 Proportion of patients oxygen free at day 28. Patients will be considered to be receiving supplemental oxygen therapy when they are receiving any of the following: supplemental oxygen by nasal cannula, supplemental oxygen by face mask, high flow nasal cannula (HFNC), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO) Day 1 to Day 28
Secondary Alive and free of new invasive mechanical ventilation at day 28 Proportion of patients alive free of new invasive mechanical ventilation at day 28 Day 1 to Day 28
Secondary 28-day mortality Proportion of patients alive at Day 28 Day 28
Secondary 60-day mortality Proportion of patients alive at Day 60 Day 60
Secondary 90-day mortality Proportion of patients alive at Day 90 Day 90
Secondary Clinical status assessed using World Health Organization (WHO) 8-point ordinal scale at Day 14 Ambulatory - Not hospitalized and no limitation of activities
Ambulatory - Not hospitalized with limitation of activities or home oxygen use
Hospitalized Mild Disease - Hospitalized, no oxygen therapy
Hospitalized Mild Disease - Hospitalized, oxygen by mask or nasal prongs
Hospitalized Severe Disease - Non-invasive ventilation or high-flow nasal cannula
Hospitalized Severe Disease -Invasive mechanical ventilation
Hospitalized Severe Disease - Invasive mechanical ventilation plus additional organ support with- vasopressors, RRT, or ECMO
Dead
Day 14
Secondary Clinical status assessed using WHO 8-point ordinal scale at Day 28 Ambulatory - Not hospitalized and no limitation of activities
Ambulatory - Not hospitalized with limitation of activities or home oxygen use
Hospitalized Mild Disease - Hospitalized, no oxygen therapy
Hospitalized Mild Disease - Hospitalized, oxygen by mask or nasal prongs
Hospitalized Severe Disease - Non-invasive ventilation or high-flow nasal cannula
Hospitalized Severe Disease -Invasive mechanical ventilation
Hospitalized Severe Disease - Invasive mechanical ventilation plus additional organ support with- vasopressors, RRT, or ECMO
Dead
Day 28
Secondary Clinical status assessed using WHO 8-point ordinal scale at Day 60 Ambulatory - Not hospitalized and no limitation of activities
Ambulatory - Not hospitalized with limitation of activities or home oxygen use
Hospitalized Mild Disease - Hospitalized, no oxygen therapy
Hospitalized Mild Disease - Hospitalized, oxygen by mask or nasal prongs
Hospitalized Severe Disease - Non-invasive ventilation or high-flow nasal cannula
Hospitalized Severe Disease -Invasive mechanical ventilation
Hospitalized Severe Disease - Invasive mechanical ventilation plus additional organ support with- vasopressors, RRT, or ECMO
Dead
Day 60
Secondary Hospital-free days through day 28 Days alive and not hospitalized during the first 28 days following randomization. Patients who die on or before day 28 are assigned a value -1. Day 1 to Day 28
Secondary Ventilator-free days through day 28 Days alive and not receiving mechanical ventilation during the first 28 days following randomization. Patients who die on or before day 28 are assigned a value -1. Day 1 to Day 28
Secondary Respiratory failure-free days through day 28 Days alive and not in respiratory failure during the first 28 days following randomization. A respiratory failure-free day is defined as a day alive without the use of HFNC, NIV, IMV, or (ECMO). Patients who die on or before day 28 are assigned a value -1. Day 1 to Day 28
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure